BioSpace News Archive

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release first quarter 2022 financial results before the market open on Monday, May 16, 2022.

Achilles Therapeutics plc (NASDAQ: ACHL), today announced that the first patient has been dosed with personalized clonal neoantigen-reactive T cells, or cNeT, manufactured with the Company’s higher-dose VELOS™ Process 2 in the ongoing Phase I/IIa CHIRON clinical trial for the treatment of advanced non-small cell lung cancer (NSCLC).

Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the first quarter of 2022.

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results for the first quarter ended March 31, 2022, and noted key upcoming anticipated milestones.

TELA Bio, Inc. announced that the Company will participate in the 2022 H.C. Wainwright Annual Global Investment Conference on May 24th, 2022.

908 Devices Inc. today announced updates to its MX908 handheld mass spec device, adding new capabilities to streamline workflows and improve field safety for first responders.

AN2 Therapeutics, Inc. today announced the appointment of Maggie FitzPatrick to its Board of Directors.

Rheos Medicines today announced the peer-reviewed publication of preclinical data supporting MALT1 inhibition as a novel therapeutic strategy to treat autoimmune and inflammatory diseases.

Bio-Thera Solutions, Ltd. today announced that dosing has begun in a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of BAT7104, a bispecific antibody that specifically blocks the interaction of human PD-L1 and CD47 with their corresponding receptors.

Moderna, Inc. today announced that it will host its in-person Science and Technology Day for analysts and investors at 9:00 a.m. ET on Tuesday, May 17 in Boston, MA.